Comparative Pharmacology
Head-to-head clinical analysis: LOCAMETZ versus PALSONIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCAMETZ versus PALSONIFY.
LOCAMETZ vs PALSONIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin hydrochloride is a biguanide antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes mellitus. It primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Selective serotonin reuptake inhibitor (SSRI) that enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing extracellular serotonin levels in the brain.
Locametz (gallium Ga 68 gozetotide) is administered intravenously at a dose of 3-5 mCi (110-185 MBq) as a single injection for PET imaging. No repeated dosing schedule is defined.
70 mg/m2 IV every 3 weeks. Infusion over 60 minutes.
None Documented
None Documented
Terminal elimination half-life of 14 hours (range 12-16 h); clinically, steady-state achieved after 3 days.
Terminal half-life 12 hours (range 10–14 h) in healthy adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion (70% unchanged), with 20% fecal elimination via biliary secretion; 10% metabolized.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid